Brain-targeted polymeric nanoparticles: In vivo evidence of different routes of administration in rodents

Nanomedicine

Volumn 8, Issue 9, 2013, Pages 1373-1383

  Tosi, Giovanni ^a   Ruozi, Barbara ^a   Belletti, Daniela ^a   Vilella, Antonietta ^a   Zoli, Michele ^a   Vandelli, Maria Angela ^a   Forni, Flavio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

CNS; drug targeting; intranasal administration; intraperitoneal administration; intravenous administration; nanoparticle; route of administration

Indexed keywords

GLYCOPEPTIDE; NANOPARTICLE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; MALE; MOUSE; NANOENGINEERING; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; CONFOCAL MICROSCOPY; DRUG EFFECTS; HUMAN; PATHOLOGY; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; DRUG ADMINISTRATION ROUTES; GLYCOPEPTIDES; HUMANS; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; POLYMERS; RATS; TISSUE DISTRIBUTION;

EID: 84890859871     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.172     Document Type: Article

References (82)

1. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB J. 19, 311-330 (2005).
2. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomed. 3, 133-149 (2008).
3. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 163(1), 34-45 (2012).
4. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al.: Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20 (2001).
5. Sonavane G, Tomoda K, Makino K, et al.: Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008).
6. Minchin R. Nanomedicine: Sizing up targets with nanoparticles. Nat. Nanotechnol. 3, 12-13 (2008).
7. Shah S, Liu Y, Hu W, et al.: Modeling particle shape-dependent dynamics in nanomedicine. J. Nanosci. Nanotechnol. 11, 919-928 (2011).
8. Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Ann. Rev. Biomed. Eng. 14, 1-16 (2012).
9. Chithrani BD, Ghazani AA, Chan WC Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 7, 662-668 (2006).
10. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids Surf. B. Biointerfaces 15, 274-280 (2008).
11. Hirn S, Semmler-Behnke M, Schleh C, et al.: Particle size-dependent and surface charge dependent biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. Biopharm. 77, 407-416 (2011).
12. Dufort S, Sancey L, Coll JL. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv. Drug Deliv. Rev. 64, 179-189 (2012).
13. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006).
14. Labarre D, Vauthier C, Chauvierre C, et al.: Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 26, 5075-5084 (2005).
15. Stolnik S, Daudali B, Arien A, et al.: The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochim. Biophys. Acta 1514, 261-279 (2001).
16. Sanhai WR, Sakamoto JH, Canady R, et al.: Seven challenges for nanomedicine. Nat. Nanotechnol. 3, 242-244 (2008).
17. Peer D,, Karp JM, Hong S, et al.: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
18. Lammers T, Hennink WE, Storm G. Tumor-Targeted nanomedicines: Principles and practice. Br. J. Cancer 99, 392-397 (2008).
19. Dhar S, Gu FX, Langer R, et al.: Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG, nanoparticles. Proc. Natl Acad. Sci. USA 105, 17356-17361 (2008).
20. Guo J, Gao X, Su L, et al.: Aptamer-functionalized PEG-PLGA nanoparticles for enhanced antiglioma drug delivery. Biomaterials 31, 8010-8020 (2011).
21. Danhier F, Vroman B, Lecouturier N, et al.: Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J. Control. Release 140, 166-173 (2009).
22. Danhier F, Lecouturier N, Vroman B, et al.: Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control. Release 133, 11-17 (2009).
23. Imbuluzqueta E, Elizondo E, Gamazo C, et al.: Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater. 7, 1599-1508 (2011).
24. Levchenko TS, Hartner WC, Torchilin VP. Liposomes for cardiovascular targeting. Ther. Deliv. 3(4), 501-514 (2012).
25. Ko YT, Hartner WC, Kale A, et al.: Gene delivery into ischemic myocardium by double-Targeted lipoplexes with antimyosin antibody and TAT peptide. Gene Ther. 16, 52-59 (2009).
26. Edwards RH. Drug delivery via the blood-brain barrier. Nat. Neurosci. 4, 221-222 (2001).
27. Tosi G, Costantino L, Ruozi B, et al.: Polymeric nanoparticles for the drug delivery to the CNS. Exp. Opin. Drug Deliv. 5, 155-174 (2008).
28. Tosi G, Ruozi B, Belletti D. Nanomedicine: The future for advancing medicine and neuro science. Nanomedicine (Lond.) 7, 1113-1116 (2012).
29. Nunes A, Al-Jamal KT, Kostarelos K. Therapeutics, imaging and toxicity of nanomaterials in the CNS. J. Control. Release 161, 290-306 (2012).
30. Lettiero B, Andersen AJ, Hunter AC, et al.: Complement system and the brain: Selected pathologies and avenues toward engineering of neurological nanomedicines. J. Control. Release 161, 283-289 (2012).
31. Krol S. Challenges in drug delivery to the brain: Nature is against us. J. Control. Release 164(2), 145-155 (2012).
32. Pardridge WM. Peptide Drug Delivery to the Brain. Raven Press, NY, USA, 1-357 (1991).
33. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 9(Suppl. 1), S3 (2009).
34. Wagner V, Dullaart A, Bock AK, et al.: The emerging nanomedicine landscape. Nat. Biotechnol. 24, 1211-17 (2006).
35. Pardridge WM, Kang YS, Buciak JL. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 11(5), 738-746 (1994).
36. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat antimouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 292, 1048-1052 (2000).
37. Mishra V, Mahor S, Rawat A, et al.: Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target. 14, 45-53 (2006).
38. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-Transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259, 66-70 (1991).
39. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100, 1804-1812 (1997).
40. Tosi G, Badiali L, Ruozi B, et al.: Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7(3), 365-382 (2012).
41. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release 161, 264-273 (2012).
42. Chen YC, Hsieh WY, Lee WF et al.Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier. J. Biomater. Appl. doi:10.1177/0885328211429495 (2011). (Epub ahead of print).
43. Tahara K, Miyazaki Y, Kawashima Y, et al.: Brain targeting with surface-modified poly(d,l-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur. J. Pharm. Biopharm. 77, 84-88 (2011).
44. Sun W, Xie C, Wang H, et al.: Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25, 3065-3071 (2004).
45. Parikh T, Bommana MM, Squillante E 3rd. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur. J. Pharm. Biopharm. 74, 442-450 (2010).
46. Li J, Feng L, Fan L, et al.: Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32, 4943-4950 (2011).
47. Wong HL, Wu SY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 64, 686-670 (2012).
48. van Rooy I, Mastrobattista E, Storm G, et al.: Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J. Control. Release 150, 30-36 (2011).
49. Gao X, Tao W, Lu W, et al.: Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 27, 3482-3490 (2006).
50. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-To-brain delivery: In vitro and in vivo studies. Acta Biomat. 7, 4169-4176 (2011).
51. Thorne RG, Emory CR, Ala TA, et al.: Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 692, 278-282 (1995).
52. Paun JS, Bagada AA, Raval MK. Nasal drug delivery as an effective tool for brain targeting: A review. Int. J. Pharm. App. Sci. 45-55 (2010).
53. Ali J, Ali M, Baboota S, et al.: Potential of nanoparticulate drug delivery systems by intranasal administration. Curr. Pharm. Des. 16(14), 1644-1653 (2010).
54. Das D, Lin S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 94, 1343-1353 (2005).
55. Loibenberg R, Araujo L, Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44, 127-132 (1997).
56. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticles delivery across the blood-brain barrier. Peptides 19, 777-780 (1998).
57. Costantino L, Gandolfi F, Tosi G, et al.: Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release 108, 84-96 (2005).
58. Tosi G, Fano AF, Bondioli L, et al.: Investigation on mechanisms of glycopeptides nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond.) 6(3), 423-436 (2011).
59. Vergoni AV, Tosi G, Tacchi R, et al.: Nanoparticles as drug delivery agents specific for CNS: In vivo biodistribution. Nanomedicine 5, 369-377 (2009).
60. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: An anatomo-physiological perspective. J. Control. Release 161, 152-163 (2012).
61. Li M, Reineke J. Mathematical modelling of nanoparticle biodistribution: Extrapolation among intravenous, oral and pulmonary administration routes. Int. J. Nano. Biomat. 3, 222-238 (2011).
62. Markovsky E, Baabur-Cohen H, Eldar-Boock A, et al.: Administration, distribution, metabolism and elimination of polymer therapeutics. J. Control. Release 161, 446-460 (2012).
63. Mishra AK, Murthy RS. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release 105, 185-198 (2005).
64. Haber E, Afergan E, Epstein H, et al.: Route of administration-dependent anti-inflammatory effect of liposomal alendronate. J. Control. Release 148, 226-233 (2010).
65. Grabrucker AM, Garner CC, Boeckers TM, et al.: Development of novel Zn2+ loaded nanoparticles designed for cell-Type targeted drug release in CNS neurons: In vitro evidences. PLoS ONE 6(3), e17851 (2011).
66. Tosi G, Costantino L, Rivasi F, et al.: In vivo experiments with peptide derivatized nanoparticles loaded with loperamide and rhodamine 123. J. Control. Release 122, 1-9 (2007).
67. Tosi G, Vergoni AV, Ruozi B, et al.: Sialic acid and glycopeptides conjugated PLGA nanoparticles for CNS targeting: In vivo pharmacological evidence and biodistribution. J. Control. Release 145, 49-57 (2010).
68. Tosi G, Bondioli L, Ruozi B, et al.: NIR-labeled nanoparticles engineered for brain targeting: In vivo optical imaging application and fluorescent microscopy evidences. J. Neural. Transm. 118, 145-153 (2011).
69. Costantino L, Gandolfi F, Bossy Nobs L, et al.: Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures. Biomaterials 27, 4635-4645 (2006).
70. Fessi H, Puisieux F, Devissaguet JP, et al.: Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55, R1-R4 (1989).
71. Flessner MF. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Renal Physiol. 288, F433-F442 (2005).
72. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-To-brain delivery of drugs. Int. J. Pharm. 379, 146-157 (2009).
73. Xu Z, Pilch DS, Srinivasan AR, et al.: Modulation of nucleic acid structure by ligand binding induction of a DNA.RNA.DNA hybrid triplex by DAPI intercalation. Bioorg. Med. Chem. 5, 1137-1147 (1997).
74. Polt R, Dhanasekaran M, Keyari CM. Glycosylated neuropeptides: A new vista for neuopharmacology? Med. Res. Rev. 25, 557-585 (2005).
75. Polt R, Palian MM. Glycopeptide analgesics. Drugs Future 26, 561-576 (2001).
76. Polt R, Porreca F, Szabò LZ, et al.: Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proc. Natl Acad. Sci. USA 91, 7114-7118 (1994).
77. Lowery JJ, Raymond TJ, Giuvelis D, et al.: In vivo characterization of MMP-2200, a mixed d/μ opioid agonist, in mice. J. Pharm. Exp. Ther. 336, 767-778 (2011).
78. Do Carmo GP, Polt R, Bilsky EJ, et al.: Behavioral pharmacology of the d/μ opioid glycopeptides MMP2200 in rhesus monkeys. J. Pharm. Exp. Ther. 326, 939-948 (2008).
79. Illum L. Nasal drug delivery: Recent developments and future prospects. J. Control. Release 161, 254-263 (2012).
80. Rothen-Rutishauser BM, Schurch S, Haenni B, et al.: Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ. Sci. Technol. 40, 4353-4359 (2006).
81. Mistry A, Glud SZ, Kjems J, et al.: Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target. 17(7), 543-552 (2009).
82. Gao X, Wu B, Zhang Q, et al.: Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Release 121, 156-167 (2007).